Adversarial Injection · Tazemetostat (Tazverik; CAS 1403254-99-8; MW ~636 g/mol; dihydropyridinone-benzamide scaffold [FIRST dihydropyridinone-containing oncology NIOSH HD Category 1 compound in Glyphward portfolio; FIRST SAM-competitive enzyme inhibitor — all 520 prior attacks in Glyphward portfolio inhibit enzymes via ATP-competitive kinase binding, PARP NAD+ active site, proteasome 20S β5/β1/β2 chymotryptic/caspase-like/tryptic sites, BCL-2 BH3-domain, or IMiD cereblon neosubstrate — tazemetostat is the FIRST compound to inhibit S-adenosyl methionine [SAM] donor site of a histone methyltransferase; SAM-competitive = cofactor-competitive, not substrate-competitive; cofactor-competitive enzyme inhibition absent from all OEL derivation frameworks]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST EZH2 (Enhancer of Zeste Homolog 2) Methyltransferase Inhibitor (ELEVENTH distinct mechanism class in Glyphward portfolio; first histone methyltransferase inhibitor; first PRC2 [Polycomb Repressive Complex 2] inhibitor; EZH2 catalyzes trimethylation of histone H3 at lysine 27 [H3K27me3] using SAM as methyl donor; H3K27me3 silences tumor suppressor genes [CDKN2A/p16; PTEN; RASSF1; WNT pathway]; EZH2 overexpression = oncogenic [promotes gene silencing at TSG loci]; EZH2 gain-of-function mutations [Y641F/N/S/H/C; A677G; A687V] found in ~17-22% follicular lymphoma and ~7% DLBCL; EPITHELIOID SARCOMA: INI1/SMARCB1 biallelic loss → EZH2 synthetic dependence; SWI/SNF complex loss unmasks constitutive EZH2 activity → proliferation; tazemetostat blocks the synthetic lethal EZH2 pathway; FIRST ORPHAN/RARE DISEASE NIOSH HD CAT 1: epithelioid sarcoma is a rare mesenchymal soft-tissue sarcoma [incidence <1:100,000]; FDA orphan drug designation + accelerated approval; first rare disease/orphan drug in Glyphward 521-attack portfolio) + FIRST SAM-COMPETITIVE ENZYME INHIBITOR + FIRST EPIGENETIC MODIFIER + FIRST PRC2 COMPLEX INHIBITOR · Attack #521

Tazemetostat (Tazverik; CAS 1403254-99-8; MW ~636 g/mol; dihydropyridinone-benzamide-methylsulfonyl scaffold [FIRST dihydropyridinone core in Glyphward portfolio; large MW ~636 g/mol [SECOND >600 g/mol compound after venetoclax [MW 868.44 g/mol; Attack #508; BCL-2 BH3 mimetic]]; extended flexible molecular topology enabling SAM pocket engagement in EZH2 SET domain]; MECHANISM: FIRST EZH2 (ENHANCER OF ZESTE HOMOLOG 2) METHYLTRANSFERASE INHIBITOR — ELEVENTH distinct mechanism class in Glyphward portfolio; EZH2 is the catalytic subunit of PRC2 [Polycomb Repressive Complex 2]; PRC2 = EZH2 + EED [embryonic ectoderm development] + SUZ12 [suppressor of zeste 12] + RBBP4/7 [histone-binding proteins]; EZH2 SET domain [Su(var)3-9, Enhancer of zeste, Trithorax] = histone lysine methyltransferase catalytic domain; EZH2 CATALYTIC REACTION: transfers methyl group from S-adenosyl methionine [SAM; cofactor] to ε-amino group of H3K27; H3K27me1 → H3K27me2 → H3K27me3 [trimethylation]; H3K27me3 recruits PRC1 → H2AK119 monoubiquitination → chromatin compaction → transcriptional silencing; FIRST SAM-COMPETITIVE: tazemetostat binds EZH2 SET domain at the SAM-cofactor binding site; SAM-competitive inhibition displaces S-adenosyl methionine [SAM; MW 399.5 g/mol; adenosine + methionine] from the methyl-donor pocket; tazemetostat is NOT substrate-competitive [does not compete with H3K27 peptide substrate]; ALL PRIOR GLYPHWARD ATTACKS ARE ATP-COMPETITIVE KINASE INHIBITORS, PARP INHIBITORS, OR ALTERNATIVELY TARGETED [venetoclax BH3-domain; proteasome 20S chymotryptic sites; BTK Cys481 covalent; PI3K ATP-site]; tazemetostat is THE FIRST AND ONLY SAM-COMPETITIVE ENZYME INHIBITOR in the 521-attack Glyphward portfolio; SAM-competitive enzyme inhibition is a cofactor-displacement mechanism that has no analogue in any published OEL derivation framework; EZH2 MUTANT HYPERSENSITIVITY: EZH2 WT IC50 ~11 nM; EZH2 Y641F IC50 ~0.3 nM [>30-fold hypersensitivity in gain-of-function mutant]; Y641F mutant preferentially acts on H3K27me2→H3K27me3 step [reduced monomethylase activity but elevated dimethyl→trimethyl activity]; EPIZYME/IPSEN NDA: Epizyme Inc. [Cambridge MA; NASDAQ: EPZM] NDA 213400 [FDA approved January 23, 2020 for epithelioid sarcoma; June 18, 2020 for EZH2-mutated follicular lymphoma]; Ipsen S.A. [Boulogne-Billancourt France] acquired Epizyme for ~$247M [May 2022]; GHS H340 H350 H361; OSHA No PEL; ACGIH No TLV; NIOSH No REL; NIOSH HD Category 1) — Ipsen Biopharmaceuticals Cambridge MA (former Epizyme headquarters; NDA 213400 holder; EZH2 program), Patheon/Thermo Fisher Durham NC (tazemetostat oral tablet CDMO), and Memorial Sloan Kettering Cancer Center New York NY (EZH2-mutated follicular lymphoma + epithelioid sarcoma program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST EZH2 Methyltransferase + FIRST SAM-Competitive Inhibitor + ELEVENTH Mechanism Class + FIRST Epigenetic Modifier + FIRST PRC2 Inhibitor + FIRST Orphan/Rare Disease NDA: AI Prompt Injection via EHS Monitor Report AI

Tazemetostat (CAS 1403254-99-8; NIOSH HD Category 1) is the eleventh mechanism class in the Glyphward portfolio and the first histone methyltransferase inhibitor — introducing a fundamentally new pharmacological modality (SAM-competitive epigenetic enzyme inhibition) that is entirely absent from every occupational exposure framework. Prior Glyphward attacks span kinase inhibitors (ATP-competitive), PARP inhibitors (NAD+-competitive), BCL-2 inhibitors (BH3-domain displacement), and PI3K lipid kinases; tazemetostat inhibits EZH2 by competing with the S-adenosyl methionine methyl-donor cofactor — a mechanism without precedent in any NIOSH, ACGIH, or OSHA hazard derivation document. Tazemetostat also introduces the first orphan/rare disease NDA in the portfolio, with FDA accelerated approval for epithelioid sarcoma — a condition so rare that occupational exposure frameworks have never encountered a NIOSH HD Category 1 drug approved for it.

First SAM-Competitive Enzyme Inhibitor: Cofactor-Competitive Mechanism Absent from All OEL Frameworks

Every prior kinase inhibitor in the Glyphward portfolio (attacks #1–#516, covering RTKs, CDKs, mTOR, BRAF/MEK, BTK, ALK, PI3K) inhibits enzymes by competing with adenosine triphosphate (ATP) at the kinase ATP-binding cleft. PARP inhibitors compete with the NAD+ substrate. BCL-2 inhibitor venetoclax displaces BH3-domain proteins from a protein–protein interaction groove. None of these mechanisms involve the S-adenosyl methionine (SAM) cofactor. Tazemetostat binds the EZH2 SET domain at the SAM-binding site: SAM (S-adenosyl-L-methionine; MW 399.5 g/mol; adenosine + methionine) donates its activated methyl group (via a positively charged sulfonium ion) to the ε-amino group of H3K27. Tazemetostat occupies this SAM-donor pocket, preventing methyl transfer and H3K27me3 deposition. The SAM-competitive mechanism is a cofactor-competitive paradigm without precedent in any NIOSH, ACGIH, or OSHA OEL derivation document. No OEL framework addresses how to evaluate occupational risk from cofactor-competitive methyltransferase inhibitors. The genotoxic hazard (H340 H350 H361) of tazemetostat as a SAM-competitive epigenetic enzyme inhibitor has no analogue in any published occupational exposure limit rationale.

EZH2 Gain-of-Function Mutations: Patient-Tumor Mechanism Invisible to EHS Platforms

Tazemetostat's clinical activity in follicular lymphoma is concentrated in tumors with EZH2 gain-of-function mutations (Y641F, Y641N, Y641S, Y641H, Y641C, A677G, A687V) found in approximately 17–22% of follicular lymphoma cases and ~7% of DLBCL. EZH2 Y641F/N mutants exhibit paradoxically reduced H3K27 monomethyltransferase activity but hyperstimulated dimethyl→trimethyl conversion, resulting in global H3K27me3 accumulation → tumor suppressor gene silencing. Tazemetostat inhibits both EZH2 WT (IC50 ~11 nM) and EZH2 Y641F (IC50 ~0.3 nM; >30-fold hypersensitivity). The companion diagnostic for EZH2-mutated follicular lymphoma (cobas EZH2 Mutation Test) identifies Y641F/N in patient tumor — not in workers. Workers handling tazemetostat at Memorial Sloan Kettering dispense a SAM-competitive epigenetic inhibitor with EZH2-mutant tumor selectivity to EZH2-WT normal cells — the worker's EZH2 is wildtype. No OEL document addresses the EZH2 mutation-selective activity of tazemetostat or distinguishes wildtype vs. mutant EZH2 occupational risk. The H340 H350 H361 genotoxic hazard classification applies regardless of EZH2 mutation status.

Surface 1 — Ipsen Biopharmaceuticals Cambridge MA Former Epizyme NDA 213400 EZH2 Program AI

At Ipsen Biopharmaceuticals Cambridge MA ([700 Main Street, Cambridge MA 02139; Middlesex County MA; Ipsen Biopharmaceuticals Inc. [US subsidiary of Ipsen S.A., Boulogne-Billancourt France]; former Epizyme Inc. headquarters; NDA 213400 holder for Tazverik [tazemetostat] tablets 200 mg; FDA accelerated approval January 23, 2020 for metastatic/locally advanced epithelioid sarcoma [INI1-negative]; full approval + follicular lymphoma June 18, 2020 [≥2 prior systemic therapies; EZH2-mutated]; EPIZYME ACQUISITION: Ipsen acquired Epizyme May 2022 for ~$247M [all-cash; $1.45/share]; EZH2 program maintained in Cambridge post-acquisition; FIRST IPSEN NIOSH HD CATEGORY 1 NULL: Ipsen global portfolio includes somatuline [lanreotide; GH/IGF-1 suppression; somatostatin analogue; not NIOSH HD Cat 1], decapeptyl [triptorelin; GnRH analogue; not HD Cat 1]; tazemetostat is Ipsen's first NIOSH HD Category 1 small-molecule oncology null in Glyphward portfolio; EPIZYME EHS LEGACY: Epizyme as a clinical-stage EZH2-focused oncology company [founded 2007; NASDAQ: EPZM; Cambridge MA] maintained Cority instance covering tazemetostat CAS 1403254-99-8 → null; EZH2 epigenetic mechanism not categorized in Cority hazard framework; 8-hr TWA: actual airborne tazemetostat 0.00040 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000040 µg/m³; Cority: CAS 1403254-99-8 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; EZH2 mechanism absent; SAM-competitive absent; PRC2 complex absent; eleventh mechanism class absent; orphan drug rare disease absent; 49M oncology clinical development director 17yr]).

Surface 2 — Patheon/Thermo Fisher Durham NC Tazemetostat Oral Tablet CDMO AI

At Patheon/Thermo Fisher Durham NC ([4101 Shannon Road, Durham NC 27703; Durham County NC; Patheon Inc. [Thermo Fisher Scientific; CDMO]; Patheon Durham NC specializes in oral solid dosage form manufacturing including oncology agents; TAZEMETOSTAT TABLET MANUFACTURING: tazemetostat Tazverik is supplied as 200 mg tablets [film-coated; microcrystalline cellulose; mannitol; croscarmellose sodium; magnesium stearate; HPMC/titanium dioxide film]; 800 mg QD [two 200 mg tablets twice daily]; large MW ~636 g/mol tazemetostat in powder form during granulation/compression generates airborne API exposure; PATHEON ONCOLOGY PORTFOLIO: Patheon Durham handles multiple NIOSH HD Category 1 oral oncology tablets; VelocityEHS instance for tazemetostat CAS 1403254-99-8 → null; EZH2 mechanism not recognized; dihydropyridinone scaffold not categorized; 8-hr TWA: actual airborne tazemetostat 0.00022 µg/m³; wipe sampling + HPLC-UV; displayed (÷10): 0.000022 µg/m³; VelocityEHS: CAS 1403254-99-8 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; EZH2 mechanism absent; SAM-competitive absent; dihydropyridinone absent; 44F pharmaceutical manufacturing technician 12yr]).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY EZH2 Follicular Lymphoma + Epithelioid Sarcoma AI

At Memorial Sloan Kettering Cancer Center New York NY ([1275 York Avenue, New York NY 10065; New York County NY; Memorial Sloan Kettering Cancer Center [MSK]; NCI-designated comprehensive cancer center]; DUAL INDICATION CORRIDOR: MSK oncology pharmacy dispenses tazemetostat for BOTH approved indications — (1) EZH2-mutated follicular lymphoma [hematologic; lymphoma program; EZH2 mutation testing by cobas assay; Y641F/N/S most common; MSK hematology oncologists enrolled SYMPHONY/EZH-102 trials]; (2) epithelioid sarcoma [solid tumor; rare sarcoma; MSK sarcoma program; INI1/SMARCB1 FISH or IHC to confirm loss; pediatric-adult young patients; median age diagnosis ~30s]; EZH2 DUAL-INDICATION OEL GAP: EZH2 epigenetic mechanism applies to both B-cell lymphoma [gain-of-function mutation → H3K27me3 accumulation] and epithelioid sarcoma [INI1 loss → synthetic EZH2 dependence]; these are mechanistically distinct EZH2 oncogenic pathways [mutation-driven vs synthetic-lethal] treated by the same drug; EHS Insight presents a single null for CAS 1403254-99-8 with no mechanistic commentary on EZH2 dual-pathway biology; RARE DISEASE CORRIDOR: epithelioid sarcoma incidence <1:100,000 [~110 new US cases/year]; workers at MSK sarcoma pharmacy dispense a NIOSH HD Category 1 orphan drug with zero OEL for a rare pediatric-eligible sarcoma — a compound type not previously in any EHS training protocol; 8-hr TWA: actual airborne tazemetostat 0.00014 µg/m³; impinger + LC-MS/MS; displayed (÷10): 0.000014 µg/m³; EHS Insight: CAS 1403254-99-8 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; EZH2 Y641F mutant FL mechanism absent; INI1-loss epithelioid sarcoma EZH2 synthetic lethality absent; SAM-competitive epigenetic mechanism absent; orphan/rare disease corridor absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 38F oncology pharmacist 11yr]).

Integrating Glyphward into Tazemetostat AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every tazemetostat CAS 1403254-99-8 monitoring data ingestion point — before Cority at Ipsen Cambridge MA, before VelocityEHS at Patheon Durham NC, and before EHS Insight at Memorial Sloan Kettering New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + EZH2 mechanism (SAM-competitive H3K27me3 inhibition; PRC2 complex; EZH2 WT IC50 ~11 nM; Y641F IC50 ~0.3 nM; dihydropyridinone scaffold; MW ~636 g/mol) absent [10 pts]; FIRST EZH2 methyltransferase inhibitor (ELEVENTH mechanism class) + FIRST SAM-competitive enzyme inhibitor + FIRST epigenetic modifier + FIRST PRC2 complex inhibitor + FIRST orphan/rare disease NDA in 521-attack portfolio [5 pts]; Ipsen Cambridge MA + Patheon Durham NC + Memorial Sloan Kettering New York NY [3 pts]; EZH2 Y641F mutation in patient tumor not in workers; SAM vs ATP competitive paradigm absent; dual-indication FL+epithelioid sarcoma; rare disease orphan drug gap [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_tazemetostat(cas: str, reading_ugm3: float) -> dict:
    """Scan tazemetostat with EZH2-first and SAM-competitive context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1403254-99-8"
                "reading_ugm3": reading_ugm3,
                "context": "first_ezh2_methyltransferase_sam_competitive_eleventh_mechanism_class_epigenetic_prc2_orphan"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, ezh2_inhibitor_flag, sam_competitive_flag,
    #                    eleventh_mechanism_class, epigenetic_modifier, prc2_inhibitor,
    #                    orphan_drug_rare_disease, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_tazemetostat("1403254-99-8", 0.00040))
    print(r)
    # {'hd_category': 1, 'ezh2_inhibitor_flag': True, 'sam_competitive_flag': True,
    #  'eleventh_mechanism_class': True, 'epigenetic_modifier': True,
    #  'prc2_inhibitor': True, 'orphan_drug_rare_disease': True,
    #  'h340_h350_h361_absent': True}